168 related articles for article (PubMed ID: 36547157)
1. Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.
Hao Y; Si J; Jin J; Wei J; Xiang J; Xu C; Song Z
Curr Oncol; 2022 Dec; 29(12):9452-9460. PubMed ID: 36547157
[TBL] [Abstract][Full Text] [Related]
2. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Ho IW; Pan YL; Lai JI; Liu CY
Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Wang Y; Zhang X; Tian D; Han S; Zhang J; Nie J; Dai L; Hu W; Chen X; Ma X; Tian G; Wu D; Zhang Z; Long J; Fang J
Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N; Ponce Aix S; Cedres S; Berghmans T; Burgers S; Toffart AC; Popat S; Janssens A; Gervais R; Hochstenbag M; Silva M; Burger IA; Prosch H; Stahel R; Xenophontos E; Pretzenbaher Y; Neven A; Peters S
ESMO Open; 2023 Jun; 8(3):101576. PubMed ID: 37285717
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Ma WL; Lin CC; Hsu FM; Lee JM; Chen JS; Huang YL; Chang YL; Chang CH; Yang JC
Cancer Med; 2022 Sep; 11(18):3445-3456. PubMed ID: 35348307
[TBL] [Abstract][Full Text] [Related]
8. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
10. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
[TBL] [Abstract][Full Text] [Related]
11. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F; Seto T; Inamasu E; Toyokawa G; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Oct; 34(10):5743-7. PubMed ID: 25275083
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients.
Hao Y; Lin G; Xiang J; Wang W; Xu C; Wang Q; Cai J; Zhang Y; Song Z
Cancer Med; 2023 Mar; 12(5):5649-5655. PubMed ID: 36394097
[TBL] [Abstract][Full Text] [Related]
16. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.
Perrino M; De Pas T; Bozzarelli S; Giordano L; De Vincenzo F; Conforti F; Digiacomo N; Cordua N; D'Antonio F; Borea F; Santoro A; Zucali PA
Cancer; 2022 Feb; 128(4):719-726. PubMed ID: 34706060
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N; Umemura S; Niho S; Kirita K; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Jpn J Clin Oncol; 2015 Jul; 45(7):665-9. PubMed ID: 25840444
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for thymic carcinoma and advanced thymoma in adults.
Wei ML; Kang D; Gu L; Qiu M; Zhengyin L; Mu Y
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD008588. PubMed ID: 23970462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
